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Tumor growth promotes the expansion of CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells that counteract 
T cell–mediated immune responses. An inverse correlation between natural killer (NK) cell 
activation and T reg cell expansion in tumor-bearing patients, shown here, prompted us to 
address the role of T reg cells in controlling innate antitumor immunity. Our experiments 
indicate that human T reg cells expressed membrane-bound transforming growth factor 
(TGF)–
 
 
 
, which directly inhibited NK cell effector functions and down-regulated NKG2D 
receptors on the NK cell surface. Adoptive transfer of wild-type T reg cells but not TGF-
 
 
 
 
 
/
 
 
 
 
T reg cells into nude mice suppressed NK cell–mediated cytotoxicity, reduced NKG2D receptor 
expression, and accelerated the growth of tumors that are normally controlled by NK cells. 
Conversely, the depletion of mouse T reg cells exacerbated NK cell proliferation and cytotoxicity 
in vivo. Human NK cell–mediated tumor recognition could also be restored by depletion of 
T reg cells from tumor-infiltrating lymphocytes. These findings support a role for T reg cells 
in blunting the NK cell arm of the innate immune system.
 
CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells contrib-
ute to the maintenance of immune tolerance
(1, 2). T reg cells, which constitute 
 
 
 
5–10%
of CD4
 
 
 
 T cells in rodents (3), prevent the
spontaneous emergence of organ-specific au-
toimmune diseases and contribute to the estab-
lishment of dominant tolerance on infection
(4, 5) and allogeneic transplantation (6–7). T
reg cells can also curtail antitumor immune
responses in tumor-bearing animals (8–12).
Experimental depletion of T reg cells in tumor-
bearing rodents using anti-CD25 antibodies
(9) or low-dose cyclophosphamide (12–13)
improves T cell–based tumor clearance and
augments the response to DC-based therapy
(11). Cancer patients often bear increased
numbers of circulating and tumor-infiltrating
T reg cells that exert functional inhibition of
tumor-specific T cells and predict poor sur-
vival (14–17).
NK cells may participate in tumor-immune
surveillance, in particular in leukemia (18),
neuroblastoma (19), and gastrointestinal stromal
tumors (20). Tumor cell recognition by NK
cells is dictated by a balance between inhibitory
signals mediated by MHC class I molecules and
activating signals triggered by specific ligands
(21–23). One such activating signal is provided
by the MHC class I chain–related molecule
(MIC)-NKG2D system (24), which participates
in the control of epithelial tumors. In cancer
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patients, NK cell activation can be hampered by tumor-medi-
ated shedding of MICs (25), but other mechanisms might blunt
NK cell responses during therapy with systemic cytokines (26).
In this study, we determined whether tumor-driven ex-
pansion of T reg cells might impair NK cell activation in
cancer patients. We provide evidence that both in human
and in murine systems, in vitro and in vivo, T reg cells po-
tently suppress NK cell responses, including the NK cell–
mediated control of tumor expansion. Our data are compat-
ible with the hypothesis that eliminating T reg cells might
constitute a novel strategy to stimulate the innate immune
response against tumors.
 
RESULTS
NK cell functions inversely correlate with T reg cell 
frequencies in cancer patients
 
We recently reported that therapy of GIST (gastrointesti-
nal stromal tumor–bearing) patients using the c-kit ty-
rosine kinase inhibitor Gleevec, STI571 (imatinib mesy-
late) elicited enhanced NK cell effector functions in
 
 
 
50% of cases within 2 mo and that therapy-induced NK
cell activation correlated with objective responses, pro-
longing the time to progression (20). We collected 18 pa-
tients for which the levels of IFN-
 
 
 
 secreted by circulat-
ing NK cells after ex vivo stimulation were significantly
enhanced by therapy with imatinib mesylate and 13 cases
for which NK cells were not induced (P 
 
 
 
 0.05; Fig. 1
A). In parallel, the percentages and absolute numbers of
circulating CD4
 
 
 
CD25
 
high
 
 T reg cells were monitored by
flow cytometry before therapy (Fig. 1 B) (27). In contrast
to CD4
 
 
 
CD25
 
low
 
 T cells, these CD4
 
 
 
CD25
 
high
 
 T reg
cells, purified by cell sorting or immunocapture with
magnetic beads, exhibited inhibition of allogeneic T lym-
phocyte proliferation (Fig. 1 C). The mean percentages of
T reg cells among CD3
 
 
 
CD4
 
 
 
 T cells in GIST patients
displaying NK cell induction were not elevated as com-
pared with normal volunteers (1.1 
 
 
 
 0.3% in GIST vs.
1.2% 
 
 
 
 0.4% in normal volunteers [NVs]; P 
 
  
 
0.5),
whereas these yields were significantly increased in the
group of patients with no NK cell induction (3.2 
 
 
 
 0.8%,
P 
 
  
 
0.02; absolute numbers shown in Fig. 1 D). It is
noteworthy that the tumor volume or tumor growth
could not account for these differences because there was
no correlation between tumor volumes and the T reg cell
numbers or NK cell induction (unpublished data). In ad-
dition, the frequency of circulating T reg cells was not in-
fluenced by imatinib mesylate therapy, as assessed by
follow-up examinations performed at 2-mo intervals
(unpublished data) in both groups of patients. We con-
 
Figure 1. Inverse correlation between T reg cell numbers and NK 
cell induction in GIST patients treated with imatinib mesylate.
 
 
(A) Prospective analysis of NK cell IFN-
 
 
 
 secretion after stimulation with 
allogeneic iDCs in the presence of LPS for 40 h at a ratio of 10:1 as previously 
described (reference 20) was conducted on 31 GIST patients before and 
2 mo after the onset of therapy with imatinib mesylate. The levels of IFN-
 
 
 
 
accumulating in the co-culture were assessed using an ELISA kit. Dots 
correspond to individual patients or controls. Intraindividual variations for 
the standardized assay of co-culture was 
 
 
 
10%. NK cell induction was 
defined as a 5–10-fold increase at 2 mo over baseline levels (
 
 
 
1,000 pg/ml) 
of IFN-
 
 
 
 produced by NK cells stimulated by the same allogeneic iDCs 
(
 
n
 
 
 
 
 
 18, NK cell induction; 
 
n
 
 
 
 
 
 13, no NK cell induction; and 
 
n
 
 
 
  
 
13, NVs). 
The Wilcoxon two sample rank sum test was used to compare the two-paired 
groups (*, P 
 
  
 
0.05). The horizontal line indicates the mean. (B) FACS analyses 
were performed on CD3
 
 
 
CD4
 
 
 
CD25
 
 
 
 T cells using three-color staining 
with anti-CD3–FITC, anti-CD4–PerCP, and anti-CD25–PE to identify T reg 
cells (CD4
 
 
 
CD25
 
high
 
). The y axis indicates CD25. High, CD4
 
 
 
CD25
 
high
 
 T cells; 
Low, CD4
 
 
 
CD25
 
low
 
 T cells. (C) CD4
 
 
 
CD25
 
high
 
 (T reg cells) or CD4
 
 
 
CD25
 
low 
 
T cells were cell sorted using a cell-sorter cytometer. Likewise, CD4
 
 
 
CD25
 
 
 
 
or T reg cells (CD4
 
 
 
CD25
 
 
 
) were selected by magnetic selection. Each of 
these subsets were cultured with bulk T cells and allogeneic iDCs in a 10:
10:1 ratio. Proliferation was determined after 5 d of culture by measure-
ment of [
 
3
 
H]thymidine incorporation. The values represent the means 
 
 
 
 
SEM. *, P
 
   
 
0.05 using Student’s 
 
t
 
 test. (D) Absolute numbers of circulating 
CD4
 
 
 
CD25
 
high
 
 T cells from all GIST patients classified as stated in A as “NK 
induction” versus “no NK induction” and from a panel of normal volunteers 
using FACS analyses. The data are represented as the means 
 
 
 
 SEM of the 
absolute numbers of CD4
 
 
 
CD25
 
high
 
 T cells/mm
 
3
 
 of blood. *, P 
 
  
 
0.05 using 
Student’s 
 
t
 
 test. 
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firmed that T reg cell numbers could predict NK cell in-
duction induced by immunotherapy in another trial (un-
published data). Hence, only those patients that have low
T reg cell levels manifested an increase in NK cell func-
tion after in vivo stimulation.
 
Human T reg cells inhibit NK cell functions in vitro
 
To directly assess the capacity of T reg cells to interfere with
NK cell activity, we co-cultured NK cells isolated from ei-
ther GIST patients or NVs with T reg cells from NVs. Al-
though CD4
 
 
 
CD25
 
 
 
 conventional T cells (T conv) did not
Figure 2. Inhibition of NK cell functions by T reg cells in vitro: rescue 
by IL-2R  chain–dependent cytokines. NK cells purified from GIST patients 
(A) or NVs (B) were cultured 4 h with T reg cells or with T conv isolated from 
NVs before incubation with 51Cr-labeled K562 or GIST 882 tumor targets. 
The T cell/NK cell/ target ratio was 10:10:1. Results of the chromium release 
assay are represented as means   SEM of triplicate wells from one repre-
sentative experiment out of three. (C) Same as in A and B, but with a variable 
T cell/NK cell ratio (as indicated) against GIST 882. (D) Same as in A and B, 
but using T reg cells fixed in 0.5% paraformaldehyde for 10 min. *, P   0.05 
using Fisher’s exact method in A–D. (E) Preincubation of NV-derived NK 
cells with T reg cells at 1:1 ratio for 2 h before stimulation with IL-2 or 
IL-12 (at increasing dosages overnight) or 500 IU/ml IL-4 or 10 ng/ml IL-7. 
The cytolytic activity against K562 was determined in a 51Cr release assay 
as a percentage of residual inhibition compared with NK cell activity in the 
absence of T reg cells. Data from one representative experiment out of two 
are shown as mean percentages of lysis inhibition   SEM of triplicate 
wells. (F) NK cells isolated from NVs were co-cultured with T reg cells or 
with T conv or with 1 ng/ml of TGF- 1. After a 6-h incubation, 200 IU/ml 
rhuIL-2, 2 ng/ml rhuIL-12, or 1 ng/ml IL-15 was added to the co-culture. 
18 h later, supernatants were harvested, and IFN-  levels were determined 
using an ELISA test. The means   SEM of triplicate wells from one repre-
sentative experiment out of three are shown. **, P   0.05.NK CELL INHIBITION BY T REG CELLS | Ghiringhelli et al. 1078
hamper NK cell recognition of K562 and GIST882 targets,
T reg cells strongly decreased NK cell cytotoxicity, and this
inhibition was similar for NK cells from tumor-bearing pa-
tients (Fig. 2 A) and NVs (Fig. 2 B) at a T reg cell/NK cell
ratio of 1:1. T reg cell–mediated NK cell inhibition was sig-
nificant up to a 1:5 T reg cell/NK cell ratio using NK cells
from GIST patients (P   0.05; Fig. 2 C and Fig. S1 A,
available at http://www.jem.org/cgi/content/full/jem.
20051511/DC1) or NVs (not depicted). Importantly, T reg
cells maintained their inhibitory functions even after fixa-
tion in formaldehyde, suggesting the involvement of
membrane-bound molecules (Fig. 2 D and Fig. S1 B). The
inhibitory effect of T reg cells on NK cell lysis could be
overcome by physiological doses of cytokines signaling via
the IL-2R  chain (IL-2, IL-4, and IL-7) and by supraphysi-
ological doses of IL-12 (Fig. 2 E and Fig. S2). T reg cells,
like soluble TGF- , inhibited NK cells to secrete IFN- 
on stimulation with IL-12 (at any dosing, i.e., 0.5, 10, or 50
ng/ml; not depicted) but not IL-2 and IL-15 (Fig. 2 F).
Hence, T reg cells inhibit NK cell cytolysis and IL-12–
mediated IFN-  secretion, but such an inhibition is a selective
process depending on the NK cell–stimulating trigger.
The role of membrane-bound TGF-  in T reg 
cell–mediated inhibition
In view of the controversial role of membrane-bound TGF- 
in T reg cell–induced T cell suppression (28–30), we per-
formed four-color flow cytometry stainings, measuring the
expression of membrane-associated TGF- 1 on human rest-
ing T reg cells. CD3 /CD4 /CD25high T reg cells (but not
T conv or CD3 /CD4 /CD25low cells) expressed TGF- 1
on the cell surface, as detectable with the AF-101-NA poly-
clonal chicken IgY (Fig. 3 A). As a specificity control, this
staining was abolished by competition with saturating con-
centrations of soluble TGF-  (Fig. 3 B), and, additionally,
the latent-associated protein (LAP)—which is noncovalently
linked to TGF- —was selectively expressed on T reg cells
(Fig. 3 C). However, when cultured alone or together with
NK cells, T reg cells did not secrete ELISA-detectable ( 1
fmol) levels of TGF- 1. Importantly, the neutralizing anti–
TGF- 1 antibody could counteract the inhibitory effect of T
reg cells on NK cell lytic activity against both tumor lines
(Fig. 4 A and Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20051511/DC1), whereas recombinant
soluble TGF-  mimicked the inhibitory effect of T reg cells
Figure 3. Selective expression of membrane-bound TGF-  on T reg 
cells. (A) TGF-  expression was investigated on both CD4 CD25high versus 
CD4 CD25low cells in flow cytometry using four-color staining with anti-
CD3–APC, anti-CD4–PerCP, anti-CD25–PE, anti–TGF- –FITC (AF-101-NA 
polyclonal chicken IgY), or a chicken IgY–FITC (AB-101-C) as a control 
antibody. (B) The specificity of the staining with the AF-101-NA polyclonal 
chicken IgY antibody was tested using saturating concentrations of recombi-
nant TGF- , which blocked the detection of membrane-bound TGF- . 
(C) Expression of LAP and TGF- –RII was also analyzed in flow cytometry 
on these CD3 CD4  T cell subsets in four-color staining.JEM VOL. 202, October 17, 2005 1079
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on NK cell–mediated target cell lysis (Fig. 4 A). Similarly,
the neutralizing anti–TGF- 1 antibody could restore the ca-
pacity of NK cells to respond to IL-12 for IFN-  secretion
in the presence of T reg cells (Fig. 4 B).
Soluble TGF-  reportedly (31) down-regulates the ex-
pression of natural cytotoxicity receptor NKp30 and
NKG2D receptors, thereby hampering recognition of target
Figure 4. Role of membrane-bound TGF-  in T reg cell–
mediated NK cell inhibition. (A) NK cells were co-cultured for 4 h 
with T reg cells or soluble TGF- 1 and/or a TGF- 1 blocking antibody 
or IgY control antibody before incubation with 51Cr-labeled GIST 882 
tumor targets. The T cell/NK cell/target ratio was 10:10:1. y axis   % 
specific lysis K562. The results of one representative experiment out 
of three are shown. Values represent means   SEM of triplicate wells. 
*, P   0.05 using Fisher’s exact method. (B) Incubation of NK cells with 
T reg cells for 6 h before stimulation with 2 ng/ml of IL-12 for 18 h. 
Supernatants were collected for ELISA assaying IFN-  levels. Values 
represent means   SEM of triplicate wells. The results of one repre-
sentative experiment out of three are shown. *, P   0.05. (C, left) NK 
cells were cultured alone or with T reg cells at a 1:1 ratio or with 
1 ng/ml of TGF- 1. After an overnight incubation, cells were analyzed 
by three-color staining flow cytometry (CD3–FITC, NKG2D–PE, and 
CD56–PC5). (right) Same as in the left panel, but comparing T reg cells 
with T conv or adding anti–TGF-  blocking antibody or IgY control 
antibody along with T reg cells.
Figure 5. Adoptive transfer of T reg cells in nude mice. (A) Three 
C57BL/6 nude mice were injected with PBS or with 2   106 T reg cells or T 
conv twice 3 d apart. On day 4, the cytolytic activity of splenocytes against 
YAC-1 cells was determined in a 51Cr release assay at a 1:200 target/effector 
ratio. It is noteworthy that  30% of NK1.1  CD3  NK cells were recovered 
in all three experimental groups at day 4. Data from one representative 
experiment out of two are shown as means of cytolytic activity of three 
spleens   SEM. *, P   0.05 using Fisher’s exact method at 95% confidence 
interval. (B) Same as in A, but using T reg cells or T conv derived from TGF.  /  
mice at a 1:100 (closed bars) or 1:50 (open bars) E/T ratio. (C) 2   106 T reg 
cells or T conv activated overnight with 10  g/ml anti-CD3, 5  g/ml 
anti-CD28, and 1,000 IU/ml IL-2 were adoptively transferred into nude mice. 
Flow cytometry analyses of spleens were performed at 24 h using three-
color staining (anti-CD3–PerCP, anti-Dx5–FITC, and anti-CD62L–APC, or 
NKG2D–PE). The experiments including three mice/group were performed 
twice with similar results. The dot plots of a representative animal are 
depicted, and the percentages correspond to NKG2D  cells among Dx5  
cells. (D) 3   105 B16-Rae or B16-WT tumor cells were inoculated in nude 
mice at day 0 and 12 h later, and 106 activated T reg cells or controls (T conv 
or PBS) were infused. Mice were killed at day 25 for the enumeration of lung 
metastases. Student’s t test at 95% confidence interval was used to compare 
both treatment groups. The graph depicts the results of two independent 
experiments including five mice/group. Values represent the means   SEM.NK CELL INHIBITION BY T REG CELLS | Ghiringhelli et al. 1080
cells that express the corresponding ligands. T reg cells also
down-regulated NKG2D (Fig. 4 C, left), yet had no effect
on the expression of NKp30 (Fig. S4 A, available at http://
www.jem.org/cgi/content/full/jem.20051511/DC1). The
T reg cell–mediated down-regulation of NKG2D expression
was reversed by the neutralizing anti–TGF-  antibody (Fig.
4 C, right). In addition, T reg cells prevented NK cell recog-
nition of NKG2D-Fc  targets (Fig. S4 B, GIST882 and
K562), and this effect was again blocked by anti–TGF-  an-
tibody. NK cell recognition of K562 and GIST882 tumor
cells were found to be partially dependent on the MIC/
ULBP-NKG2D molecular pathway because target lysis was
impaired by anti-NKG2D antibody, NKG2D-Fc, or soluble
MHC class I–related chain A (MICA) molecules (Fig. S4 C),
indicating that T reg cell–mediated, TGF- –dependent in-
hibition of NK cytotoxicity is associated with the down-
regulation of NKG2D.
Inhibition of NK cell function by T reg cells 
in the murine system
Athymic nu/nu mice lack thymus-dependent T conv as
well as T reg cells. The NK cell function of such mice can
be blocked by adoptive transfer of histocompatible T reg
cells (but not T conv), which abolished the natural cyto-
toxicity of splenocytes against the NK target cell line
YAC-1 (Fig. 5 A). However, in line with the role of mem-
brane-bound TGF-  expressed by human resting T reg
cells on human NK cell inhibition (Fig. 4), we show that
adoptive transfer of T reg cells derived from TGF-  / 
mice (at 6–10 d of age before the onset of lymphoprolifera-
Figure 6. T reg cell depletion resulted in profound NK cell activation 
in vivo. (A) BrdU was injected in Scurfy mice in parallel to WT mice to 
assess the basal NK cell proliferation in vivo at 24 h. The percentage of 
proliferating CD69/BrdU  NK cells in the gate CD3 /Dx5  cells was assessed 
by flow cytometry using four-color staining. One representative experiment 
out of three is shown in dot plots. (B) The natural cytotoxicity of splenic 
NK cells after isolation of Dx5  cells in WT and Scurfy mice was assessed 
against YAC-1 targets in a 4-h chromium release assay in vitro. The graph 
depicts means   SEM of triplicate wells in one representative mouse out 
of two. *, P   0.05. (C) Regulation of T reg cell–mediated NK cell inhibition 
in the steady state and after stimulation with LPS or DCs. WT mice received 
300  g of neutralizing anti-CD25 antibody (PC61) or rat control Ig or CTX 
at 100 mg/kg or PBS at day 7. At day 0, mice received a footpad injection 
of either 10  g/ml of LPS or 3   105 BM DCs (GM-CSF   IL- 4) and, 
simultaneously, an i.v. injection of BrdU. The graphs depict the means   
SEM of percentages of BrdU incorporating NK cells in three animals/group. 
(D) 5   105 RMA-S cells were injected i.p. in three nude mice alone (NT) 
or admixed with either 2   106 T reg cells or T conv purified from C57BL/6 
mice. Peritoneal exudates were harvested on days 1, 2, and 3 after cell 
injection. The percentages of NK1.1  CD3  NK cells in the exudates were 
determined by FACS analysis. The graph depicts the means of percentages 
of three mice/group   SEM. **, P   0.05.JEM VOL. 202, October 17, 2005 1081
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tion) into nude mice did not result in the inhibition of
YAC-1 lysis by Dx5  splenocytes (Fig. 5 B).
As in the human system (Fig. 4 C), in vivo injection of T
reg cells (but not T conv) reduced the expression of
NKG2D (but not CD62L; not depicted) on Dx5  splenic
NK cells within 24 h (Fig. 5 C). Moreover, the antitumor
effector function of NK cells was reduced by T reg cells in
vivo. A melanoma cell line (B16) transfected with the mu-
rine NKG2D ligand Rae produced more lung metastases in
nu/nu mice injected with T reg cells than in control mice,
but no such difference was observable for the WT B16 cell
line lacking NKG2D ligands (Fig. 5 D).
If T reg cells controlled NK cells in homeostatic condi-
tions, their absence should stimulate the NK cell system. In
accord with this speculation, the mouse mutant Scurfy,
which lacks the transcription factor necessary for the
development of T reg cells, Foxp3 (32), exhibited a
marked,  10-fold augmentation of proliferating (5-bromo-
2 deoxyuridine [BrdU]–incorporating) NK cells as com-
pared with WT littermates (Fig. 6 A). Although CD69 mol-
ecules were not up-regulated on those dividing NK cells
(Fig. 6 A), the natural cytotoxicity of purified Dx5  splenic
cells was markedly enhanced in Scurfy mice (Fig. 6 B). The
absence of T reg cells was hence permissive for enhanced
NK cell activity. Similarly, the depletion of T reg cells
achieved by injection of anti-CD25 mAb or immunostimu-
latory doses of cyclophosphamide (CTX) into C57BL/6
mice promoted the baseline proliferation of splenic NK cells
(Fig. 6 C). However, the T reg cell–mediated NK cell inhi-
bition was tightly regulated because CTX enhanced the pro-
liferation of LN NK cells after local injection of immature
DCs but not LPS (Fig. 6 C). i.p. injection of transporter as-
sociated with antigen presentation–deficient RMA-S cells
leads to the local recruitment/proliferation of NK cells (33).
Figure 7. Depletion of T reg cells in tumors restored tumor recog-
nition by NK cells. (A) Percentages of T and NK cells in metastatic and 
nonmetastatic draining LNs resected from a melanoma patient were de-
termined by FACS analysis using a three-color staining (CD3–FITC, CD56–PC5, 
and CD45–APC). Percentages of T reg cells were determined using anti-CD3–
FITC, anti-CD25–PE, and anti-CD4–PerCP mAbs. Data representative of 
three different experiments are shown. (B) LN cells from metastatic or 
nonmetastatic LNs depleted or not of CD25  or CD56  cells were subjected 
to lysis of autologous CURA cells or K562 at a 1:25 target/effector ratio. 
*, P   0.05. (C and D) One primary tumor and one invaded LN derived from 
two kidney cancer patients were dissociated and centrifuged on a Ficoll-
Hypaque gradient enabling isolation of mononuclear cells containing 5.6 
and 9% of T reg cells, respectively, and 1.8 and 1.2% of NK cells, respectively. 
Mononuclear cells were treated with either mAb anti-CD56 coated onto 
magnetic beads to deplete NK cells or anti-CD4 mAb magnetic beads 
followed by anti-CD25mAb magnetic beads to deplete T reg cells or both 
to deplete NK cells and T reg cells before a 4-h coincubation with 51Cr K562 
for a chromium release assay. Cytolytic activity was determined in a 4-h 
51Cr release assay. Results represent means   SEM of triplicate wells of a 
representative experiment.NK CELL INHIBITION BY T REG CELLS | Ghiringhelli et al. 1082
T reg cells (but not T conv) coinjected with such tumor cells
strongly reduced the number of i.p. NK cells (Fig. 6 D), thus
providing another line of evidence for the T reg cell–medi-
ated inhibition of the NK cell system in vivo.
Depletion of T reg cells ameliorates NK cell–mediated lysis 
of human tumor cells
We investigated the frequency of T reg cells in LNs from a
single patient receiving systemic cytokine therapy while
monitoring the cytotoxic activity of LN mononuclear cells
against the autologous melanoma cell line (CURA) estab-
lished before therapy. The percentages of CD3 /CD56 
NK cells infiltrating the metastatic and the nonmetastatic
LNs were similar (2.9 vs. 3%; Fig. 7 A). In line with previous
experiments (34), however, the percentage of T reg cells tri-
pled in the metastatic LNs (4 vs. 1.3%; Fig. 7 A). We ob-
served that the cytotoxicity against K562 and CURA was
more important in nonmetastatic LNs than in metastatic LNs
(46   4% vs. 19   3%, respectively; Fig. 7 B, right and left).
After removal of T reg cells from both LNs, the natural cy-
totoxicity was greatly enhanced in the metastatic node but
not in the nonmetastatic node (Fig. 7 B). Tumor cell recog-
nition could be ascribed to NK cells because depletion of
CD56  cells abolished the tumor lysis enhanced by T reg
cell depletion (Fig. 7 B). Similarly, in two other patients
bearing kidney carcinoma, depletion of T reg cells from tu-
mor-infiltrating mononuclear cells isolated from either a pri-
mary tumor or a metastatic LN restored recognition and lysis
of K562 in an NK cell–dependent manner (Fig. 7, C and D)
in two independent patients. Collectively, these data suggest
that T reg cells, infiltrating the tumor or residing in LNs,
suppress NK cell recognition of malignant cells in vivo.
DISCUSSION
This study demonstrates the capacity of resting T reg cells
to directly inhibit NK cell lytic and secretory functions in
vitro (Figs. 2 and 4) and to control NK cell proliferation
and cytotoxicity in vivo (Figs. 5 and 6). Our mouse and
human data show that NK cell inhibition induced by T reg
cells is mediated by membrane-bound TGF-  in vitro
(Figs. 3 and 4) and in vivo (Fig. 5 B). T reg cells keep NK
cells in check in homeostatic conditions (Figs. 5 and 6) and
during tumor growth in mice (Figs. 5 and 6) and humans
(Figs. 1 and 7) but not in conditions of IL-2R  chain or
Toll-like receptor 4 triggering (Figs. 2 and 6). Although
earlier studies suggested a potential role of T reg cells in
down-regulating NK cell effector functions in vitro (35–
37), this is the first study to provide mechanistic insights
into the inhibitory T reg cell–NK cell interaction and to
formally demonstrate the in vivo relevance of the T reg
cell–mediated inhibition of the NK cell system, both in
steady-state and inflammatory conditions in mice and in
cancer patients.
We observed that fixed human CD4 CD25  T reg
cells (from NVs or cancer-bearing patients) could restrict
NK cell effector functions in vitro through TGF-  present
on the surface of T reg cells. Human resting T reg cells
were found to express TGF-  on the surface (Fig. 3), thus
exhibiting a phenotype similar to activated mouse T reg
cells, which also expose TFG-  on their surface (whereas
resting mouse T reg cells do not) (28, 38). In line with this
finding, LAP is also selectively found on CD4 CD25high
but not on CD4 CD25low cells (Fig. 3). Neutralization of
TGF-  abrogated the inhibition of NK cell functions by
human T reg cells in vitro (Fig. 4), and this inhibition
could be mimicked by soluble TGF-  (Fig. 2). In contrast
to T reg cells derived from WT animals, T reg cells derived
from TGF-  /  mice transferred into nude mice did not
abrogate natural cytotoxicity of the recipient (Fig. 5 B).
T reg cell–bound TGF-  and soluble TGF-  have dis-
tinct biological effects on NK cells and are regulated inde-
pendently. Although both T reg cells and soluble TGF- 
down-regulated NKG2D on NK cells (Fig. 4 C) (31), only
soluble TGF-  down-regulated the natural cytotoxicity re-
ceptor p30, a protein required for the NK cell–mediated
lysis of DCs (Fig. S4 A) (30). Moreover, there was no cor-
relation between TGF-  serum levels and the frequency of
T reg cells in patients. Although T reg cell levels were su-
pranormal in two different cohorts of patients failing to ac-
tivate NK cells in response to imatinib mesylate (Figure.
1B), no elevation of TGF-  could be detected (not de-
picted). Although some of the effects of T reg cells on NK
cells could be abrogated by TGF-  neutralization (e.g.,
NK cytotoxicity and IFN-  production in Fig. 4), it is not
clear whether the T reg cell–dependent inhibition of NK
cell proliferation (detectable in the murine system) is also
mediated by TGF-  or by alternative effectors. However,
TGF-  accounts for the T reg cell–mediated down-modu-
lation of NKG2D on NK cells, which is detectable in vitro
in the human system (Fig. 4) and in vivo in the murine sys-
tem (Fig. 5). Importantly, NKG2D expression on NK cells
is reduced in a fraction of patients with colon (39) and
prostate carcinoma (25), constituting a negative prognostic
factor. However, it remains to be elucidated whether this is
effectively caused by an increase in the frequency or in the
per-cell activity of T reg cells beyond the explanations that
have been advanced thus far for NKG2D reduction,
namely an increase in serum TGF-  levels (40) or tumor
cell shedding of NKG2D ligands (25).
T reg cells have been previously shown to down-regu-
late the priming and the effector phase of cognate T cell re-
sponses, acting in an antigen-nonspecific fashion (40–42).
Thus, conditions leading to a defect in T reg cells cause au-
toimmune disease. This applies to the Scurfy mutant mice or
Foxp3 /  mice (which lack T reg cells because of the defi-
ciency of the T reg cell–specific master transcription factor
Foxp3) (32, 43), which develop a general state of autoimmu-
nity. The contribution of NK cells to this immune pathol-
ogy, however, has not been addressed thus far. 
Our data reveal a novel role for T reg cells in the regula-
tion of the innate immune system at the level of NK cells.
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ther by injection of a cytotoxic CD25-specific antibody or
by administration of immunostimulatory CTX doses) en-
hances the proliferation of NK cells, as well as their cyto-
toxic potential (Fig. 6). Based on these data, it is tempting
to speculate that NK cell functions are normally controlled
by T reg cells and that any imbalance in the frequency of T
reg cells may affect NK cell homeostasis. However, T reg
cells do not influence the production of IFN-  by NK cells
stimulated by IL-2R  chain–dependent cytokines (Fig. 2),
and it appears thus plausible that conditions leading to sig-
nificant cytokine production (such as LPS injection in Fig. 5
C, and, speculatively, acute infection) would not involve
any significant inhibition of NK cells by T reg cells (P  
0.05). However, in circumstances where IL-12 is involved
to promote perforin-dependent NKG2D-dependent cell ly-
sis, T reg cells could be potent inhibitors of tumor regres-
sion (44). Similarly, in chronic inflammatory processes, in-
cluding cancer, it is possible that T reg cells influence the
NK cell system. In favor of this contention, T reg cell fre-
quencies correlated with NK cell function in patients (Fig.
1), and depletion of T reg cells can stimulate NK cell–medi-
ated lysis of tumor cells ex vivo (Fig. 7). Thus, immuno-
pharmacological manipulations depleting T reg cells might
constitute a welcome addition to the oncologist’s armament
if stimulation of the NK cell response against malignant cell
is the therapeutic goal and if the predictable proautoim-
mune side effects of such a manipulation are manageable.
MATERIALS AND METHODS
Patients
Patients enrolled in the French Phase II trial (BRF14; Institut Gustave
Roussy/Centre Leon Berard, Novartis) testing the efficacy of imatinib mesy-
late in GIST patients were investigated according to the immunomonitoring
protocols approved by the local research and ethical committee (Comité
Consultatif de Protection des Personnes dans la Recherche Biomédicale). 80
ml of peripheral blood was drawn from patients before and after 2 mo of ima-
tinib mesylate treatment of 400 mg/day. Similarly, age- and sex-matched
NVs were enrolled in parallel investigations (Etablissement Français du Sang,
Reims, France). Informed written consent was given by all patients.
Moreover and independently from this study, LNs were resected from
a stage-IV metastatic melanoma patient 2 mo after a 6-wk systemic adminis-
tration of a combination of IFN-  and IL-2 that induced partial regression.
Two additional patients bearing primary kidney cancer and benefiting from
surgical resection of the primary lesion and LNs gave their consent to the
monitoring of NK cell activity in tumor-infiltrating mononuclear cells. PB-
MCs were isolated from blood by Ficoll density centrifugation (Ficoll-
Paque; GE Healthcare).
Mice
C57BL/6 WT nude mice and TGF.  /  mice were obtained from the
Centre d’élevage Janvier, the Mollegaard Breeding and Research Centre
A/S, and from T. Doetschman (University of Cincinnati College of Med-
icine, Cincinnati, OH), respectively, and were maintained in the animal
facility of Institut Gustave Roussy according to the animal Experimental
Ethics Committee guidelines. Scurfy mice were bred at the Institut Pas-
teur (Paris, France) by A. Freitas.
Cell lines
The GIST cell line (882) was kindly provided by J.A. Fletcher (Harvard
Medical School, Boston, MA). The CURA cell line was derived in our lab-
oratory from a primary culture of a metastatic LN in the melanoma patient
described above before therapy with IFN-  and IL-2. CURA cells did not
express HLA-ABC class I molecules as assessed by flow cytometry with
W6-32 mAb, an anti–HLA-ABC antibody (unpublished data). YAC-1
mouse cells are NK cell–sensitive Moloney virus–induced T cell lymphoma
cells of A/Sn background. B16Rae is a melanoma cell line stably transfected
with a cDNA encoding Rae (45) that has been provided by D. Raulet
(University of California, Berkeley, Berkeley, CA). All these cells were
maintained in RPMI with 10% FBS, 100 U/ml penicillin, and 100  g/ml
streptomycin (GIBCO BRL).
Cytokines, antibodies, and reagents for in vitro culture
Recombinant human IL-12, IL-15, IL-4, IL-7, and TGF- 1 were obtained
from R&D Systems. rhuIL-2 was purchased from Chiron Corp. Human
anti-NKG2D blocking antibody, NKG2D-Fc, and CTLA-4-Fc were ob-
tained from R&D Systems. Soluble MICA was provided by S. Caillat-Zuc-
man (46). To ascertain that CD4 CD25  T reg cells do express selectively
membrane-bound TGF- , we performed flow cytometry analyses directly
on fresh PBMCs (after Ficoll-Hypaque separation) using four-color staining
with anti-CD3–APC, anti-CD4–PerCP, anti-CD25–PE obtained from
Becton Dickinson, anti–TGF- –FITC (using the AF-101-NA polyclonal
chicken IgY from R&D Systems), or a chicken IgY–FITC (AB-101-C
from R&D Systems) as a control.
Purification of NK cells and T reg cells
NK cells, T reg cells, and T conv were obtained from human PBMCs by
magnetic cell separation (Miltenyi Biotec) according to the manufacturer’s
instructions. In some experiments, T reg cells were cell sorted using a cell-
sorter cytometer (FACSVantage; Becton Dickinson). Mouse T reg cells and
T conv were obtained from spleen cells using magnetic cell separation
(Miltenyi Biotec) after lysis of RBCs. CD4 CD25  T cells isolated by the
cell-sorter cytometer or magnetic sorting were enriched in population in T
reg cells because they were able to inhibit an allogenic reaction and because
they express Foxp3 mRNA using RT-PCR analysis (unpublished data). For
adoptive transfer experiments, 106 T reg cells or T conv were injected i.v.
in each nude mouse after 24 h of ex vivo activation with 10  g/ml anti-
CD3 mAb, 5  g/ml anti-CD28 mAb, and 2,000 IU/ml of IL-2 and several
cycles of washing.
Flow cytometry analysis
PBMCs and cultured cells were analyzed using a cytometer (FACSCalibur;
Becton Dickinson). Cells were stained with directly labeled antibodies in a
three-color staining analysis. The following antibodies were used: anti–human
CD3–FITC (IgG1, clone UCHT1), anti–human CD25–PE (IgG1, clone
M-A251), and anti–human CD4-PerCP (IgG1, clone RPA-T4). All of these
antibodies were obtained from Becton Dickinson. Anti–human CD56-PC5
(IgG1, clone N901) was purchased from Beckman Coulter. Anti–human LAP
and anti–TGF- RII antibody were obtained from R&D Systems. Anti–
mouse DX5 was obtained from Becton Dickinson. Magnetically selected T
reg cells or CD4 CD25  T conv were stained with anti–TGF- –FITC (using
the AF-101-NA polyclonal chicken IgY from R&D Systems) or a chicken
IgY–FITC (AB-101-C from R&D Systems) as a control and/or anti–human
NKG2D–PE (IgG1, clone 149810; R&D Systems), followed by a goat anti–
chicken immunoglobulin FITC-labeled antibody (R&D Systems).
In vitro assays
Cytotoxicity assay. NK cells were seeded at 2   104 cells/well in 96-
well plates to be used as effector cells. NK cells were incubated with T reg
cells or T conv or reagents (1 ng/ml TGF- 1, 10 ng/ml anti–TGF- 1 an-
tibody, 10 ng/ml isotype control antibody, 10  g/ml soluble MICA, 15
 g/ml NKG2D-Fc, 15  g/ml anti-NKG2D mAb, and 15  g/ml CTLA-
4–Fc) at the times indicated in the figures for each experimental setting in
200  l of AIMV culture medium (GIBCO BRL) at the indicated effector/
target ratio. NK cell cytotoxicity was measured in a standard 4-h 51Cr re-
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tained labeled target cells alone, and maximum 51Cr release was assessed by
addition of 2% cetrimide (Sigma-Aldrich). Specific cytotoxicity was calcu-
lated as follows: percent 51Cr release   100   (cpm experimental – cpm
spontaneous release) / (cpm maximum release – cpm spontaneous release).
Cytokine detection. 105 NK cells were cultured alone or with T reg cells
or T conv at a 1:1 ratio and/or reagents (1 ng/ml TGF- 1 or 10 ng/ml
anti–TGF- 1 antibody or 10 ng/ml isotype control antibody) for 6 h in 200
 l of AIMV medium. After a 6-h incubation, 2 ng/ml IL-12 or 200 UI/ml
IL-2 or 1 ng/ml IL-15 was added for 18 h. Supernatants of these co-cultures
were harvested, and IFN-  concentrations were determined by an ELISA
test kit (OptEIA; BD Biosciences) with a detection limit of 20 pg/ml.
Mixed lymphocyte allogeneic reactions. Allogeneic monocyte–derived
DCs propagated in GM-CSF and IL-4 were obtained as previously de-
scribed (20). 104 DCs were cultured with 105 T conv alone or with 105
CD4 CD25high or CD4 CD25low T cells (isolated by cell sorting or immu-
nomagnetic beads with anti-CD25/CD4 mAb) for 5 d. 0.5  Ci/well of
[3H]thymidine was added during the final 18 h. [3H]thymidine incorpora-
tion was measured by liquid scintillation counting after harvesting the cells
on glass fiber filters using an automatic cell harvester (Tomtec).
In vivo proliferation assays, assessment of natural cytotoxicity, and 
B16Rae lung metastases
Proliferation assay. In brief, animals were treated or not with 100 mg/kg
anti-CD25 mAb (PC61) or CTX at day  7 before inoculation of PBS, or
BM DCs propagated in GM-CSF and IL-4 (47) or LPS (10  g/injection) in
the footpad and BrdU i.v. to monitor NK cell proliferation in the draining
LNs at 24 h.
Tumor models. We examined the number of lung mets of B16Rae mel-
anoma cells injected at day 0 in nude mice receiving or not, 12 h later, an
infusion of 2   106 T reg cells or T conv activated overnight with 10  g/
ml anti-CD3, 5  g/ml anti-CD28, and 1,000 IU/ml IL-2 by adoptive
transfer. Combination therapy of STI571 and CTX to treat lung metastases
of B16F10 melanoma cells (3   105 at day 0) consisted of oral feeding with
150 mg/kg STI571 twice a day for 10 d and 100 mg/kg of CTX at day 6
for a death at day 12 and enumeration of lung metastases.
Cytotoxicity against YAC-1 cells. Splenocytes were either subjected to
a direct 4-h chromium release assay against YAC-1 cells, or NK cells were
first purified using anti-Dx5 mAb magnetic beads.
Statistical analyses
Student’s t test, Wilcoxon analysis, or Fisher’s exact method were used as
described in the figure legends to compare various groups in each experi-
ment using PRISM software.
Online supplemental material
Fig. S1 shows that T reg cells directly inhibit NK cell lytic functions against
K562. Fig. S2 depicts the dose response of NK cells to IL-2R  chain–
dependent cytokines for cytolytic functions. Fig. S3 shows the role of
membrane-bound TGF-  in mediating T reg cell inhibition on K562 NK
cell target recognition. Fig. S4 A depicts the differential effects of soluble
rhu–TGF-  and T reg cells on cell surface expression of NKp30 and p46
and NKG2D on human resting NK cells. K562 and GIST882 are NKG2D
ligand–expressing targets (Fig. S4, B and C). Online supplemental material
is available at http://www.jem.org/cgi/content/full/jem.20051511/DC1.
F. Ghiringhelli was supported by Assistance Publique Hôpitaux de Dijon. J. Taieb was 
supported by Assistance Publique-Hôpitaux de Paris. N. Chaput was supported by 
European Union (EU) grant QLRT-2001-00093. M. Terme was supported by AlloStem 
EU grant 503319. This work was funded by the Ligue Française contre le Cancer 
(Comités national, Saône-et-Loire, and Nievre) and INSERM.
The authors have no conflicting financial interests.
Submitted: 27 July 2005
Accepted: 29 August 2005
REFERENCES
1. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immuno-
logic self-tolerance. Cell. 101:455–458.
2. Shevach, E.M. 2002. CD4  CD25  suppressor T cells: more ques-
tions than answers. Nat. Rev. Immunol. 2:389–400.
3. Sakaguchi, S. 2004. Naturally arising CD4  regulatory T cells for im-
munologic self-tolerance and negative control of immune responses.
Annu. Rev. Immunol. 22:531–562.
4. Kullberg, M.C., D. Jankovic, P.L. Gorelick, P. Caspar, J.J. Letterio,
A.W. Cheever, and A. Sher. 2002. Bacteria-triggered CD4  T regula-
tory cells suppress Helicobacter hepaticus–induced colitis. J. Exp. Med.
196:505–515.
5. Belkaid, Y., C.A. Piccirillo, S. Mendez, E.M. Shevach, and D.L. Sacks.
2002. CD4 CD25  regulatory T cells control Leishmania major per-
sistence and immunity. Nature. 420:502–507.
6. van Maurik, A., M. Herber, K.J. Wood, and N.D. Jones. 2002. Cut-
ting edge: CD4 CD25  alloantigen-specific immunoregulatory cells
that can prevent CD8  T cell-mediated graft rejection: implications
for anti-CD154 immunotherapy. J. Immunol. 169:5401–5404.
7. Trenado, A., F. Charlotte, S. Fisson, M. Yagello, D. Klatzmann, B.L.
Salomon, and J.L. Cohen. 2003. Recipient-type specific CD4 
CD25  regulatory T cells favour immune reconstitution and control
graft-versus-host disease while maintaining graft-versus-leukemia. J.
Clin. Invest. 112:1688–1696.
8. Sasada, T., M. Kimura, Y. Yoshida, M. Kanai, and A. Takabayashi.
2003. CD4+CD25+ regulatory T cells in patients with gastrointestinal
malignancies: possible involvement of regulatory T cells in disease pro-
gression. Cancer. 98:1089–1099.
9. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Na-
kayama. 1999. Tumor rejection by in vivo administration of anti-
CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res.
59:3128–3133.
10. Sutmuller, R.P., L.M. van Duivenvoorde, A. van Elsas, T.N. Schuma-
cher, M.E. Wildenberg, J.P. Allison, R.E. Toes, R. Offringa, and C.J.
Melief. 2001. Synergism of cytotoxic T lymphocyte–associated antigen
4 blockade and depletion of CD25  regulatory T cells in antitumor
therapy reveals alternative pathways for suppression of autoreactive cy-
totoxic T lymphocyte responses. J. Exp. Med. 194:823–832.
11. Steitz, J., J. Bruck, J. Lenz, J. Knop, and T. Tuting. 2001. Depletion of
CD25( ) CD4( ) T cells and treatment with tyrosinase-related pro-
tein 2-transduced dendritic cells enhance the interferon alpha-induced,
CD8( ) T-cell-dependent immune defense of B16 melanoma. Cancer
Res. 61:8643–8646.
12. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin,
C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004.
CD4 CD25  regulatory T cells suppress tumor immunity but are
sensitive to cyclophosphamide which allows immunotherapy of estab-
lished tumors to be curative. Eur. J. Immunol. 34:336–344.
13. Turk, M.J., J.A. Guevara-Patino, G.A. Rizzuto, M.E. Engelhorn, and
A.N. Houghton. 2004. Concomitant tumor immunity to a poorly im-
munogenic melanoma is prevented by regulatory T cells. J. Exp. Med.
200:771–782.
14. Woo, E.Y., H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Ri-
ley, L.R. Kaiser, and C.H. June. 2002. Cutting edge: regulatory T cells
from lung cancer patients directly inhibit autologous T cell prolifera-
tion. J. Immunol. 168:4272–4276.
15. Woo, E.Y., C.S. Chu, T.J. Goletz, K. Schlienger, H. Yeh, G. Coukos,
S.C. Rubin, L.R. Kaiser, and C.H. June. 2001. Regulatory
CD4( )CD25( ) T cells in tumors from patients with early-stage
non-small cell lung cancer and late-stage ovarian cancer. Cancer Res.
61:4766–4772.
16. Liyanage, U.K., T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, G.
Doherty, J.A. Drebin, S.M. Strasberg, T.J. Eberlein, P.S. Goedege-
buure, and D.C. Linehan. 2002. Prevalence of regulatory T cells is in-
creased in peripheral blood and tumor microenvironment of patientsJEM VOL. 202, October 17, 2005 1085
ARTICLE
with pancreas or breast adenocarcinoma. J. Immunol. 169:2756–2761.
17. Curiel, T.J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, M. Mottram,
J.R. Evdemon-Hogan, L. Conejo-Garcia, M. Zhang, Y. Burow, et al.
2004. Specific recruitment of regulatory T cells in ovarian carcinoma
fosters immune privilege and predicts reduced survival. Nat. Med. 10:
942–949.
18. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W.D. Shlomchik,
A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effec-
tiveness of donor natural killer cell alloreactivity in mismatched he-
matopoietic transplants. Science. 295:2097–2100.
19. Castriconi, R., A. Dondero, R. Augugliaro, C. Cantoni, B.
Carnemolla, A.R. Sementa, F. Negri, R. Conte, M.V. Corrias, L.
Moretta, and C. Bottino. 2004. Identification of 4Ig-B7-H3 as a neu-
roblastoma-associated molecule that exerts a protective role from an
NK cell-mediated lysis. Proc. Natl. Acad. Sci. USA. 101:12640–12645.
20. Borg, C., M. Terme, J. Taieb, C. Menard, C. Flament, C. Robert, K.
Maruyama, H. Wakasugi, E. Angevin, K. Thielemans, et al. 2004.
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK
cell-dependent antitumor effects. J. Clin. Invest. 114:379–388.
21. Moretta, A., C. Bottino, M.C. Mingari, R. Biassoni, and L. Moretta.
2002. What is a natural killer cell? Nat. Immunol. 3:6–8.
22. Lanier, L.L. 2001. On guard–activating NK cell receptors. Nat. Immu-
nol. 2:23–27.
23. Vivier, E., J.A. Nunes, and F. Vely. 2004. Natural killer cell signaling
pathways. Science. 306:1517–1519.
24. Bauer, S., V. Groh, J. Wu, A. Steinle, J.H. Phillips, L.L. Lanier, and T.
Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor
for stress-inducible MICA. Science. 285:727–729.
25. Wu, J.D., L.M. Higgins, A. Steinle, D. Cosman, K. Haugk, and S.R.
Plymate. 2004. Prevalent expression of the immunostimulatory MHC
class I chain-related molecule is counteracted by shedding in prostate
cancer. J. Clin. Invest. 114:560–568.
26. Rosenberg, S.A., M.T. Lotze, J.C. Yang, P.M. Aebersold, W.M. Line-
han, C.A. Seipp, and D.E. White. 1989. Experience with the use of
high dose of interleukin-2 in the treatment of 652 cancer patients.
Ann. Surg. 210:474–485.
27. Baecher-Allan, C., V. Viglietta, and D.A. Hafler. 2004. Human
CD4 CD25  regulatory T cells. Semin. Immunol. 16:89–98.
28. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell contact–depen-
dent immunosuppression by CD4 CD25  regulatory T cells is medi-
ated by cell surface–bound transforming growth factor– . J. Exp. Med.
194:629–644.
29. Annunziato, F., L. Cosmi, F. Liotta, E. Lazzeri, R. Manetti, V. Vanini,
P. Romagnani, E. Maggi, and S. Romagnani. 2002. Phenotype, local-
ization, and mechanism of suppression of CD4 CD25  human thy-
mocytes. J. Exp. Med. 196:379–387.
30. Levings, M.K., R. Sangregorio, C. Sartirana, A.L. Moschin, M. Batta-
glia, P.C. Orban, and M.G. Roncarolo. 2002. Human CD4 CD25 
T suppressor cell clones produce transforming growth factor– , but
not interleukin 10, and are distinct from type 1 T regulatory cells. J.
Exp. Med. 196:1335–1346.
31. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro,
R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003.
Transforming growth factor beta 1 inhibits expression of NKp30 and
NKG2D receptors: consequences for the NK-mediated killing of den-
dritic cells. Proc. Natl. Acad. Sci. USA. 100:4120–4125.
32. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003. Foxp3 pro-
grams the development and function of CD4 CD25 regulatory T cells.
Nat. Immunol. 4:330–336.
33. Glas, R., L. Franksson, C. Une, M.L. Eloranta, C. Ohlen, A. Orn, and
K. Karre. 2000. Recruitment and activation of natural killer (NK) cells
in vivo determined by the target cell phenotype. An adaptive compo-
nent of NK cell–mediated responses. J. Exp. Med. 191:129–138.
34. Viguier, M., F. Lemaitre, O. Verola, M.S. Cho, G. Gorochov, L. Du-
bertret, H. Bachelez, P. Kourilsky, and L. Ferradini. 2004. Foxp3 ex-
pressing CD4 CD25(high) regulatory T cells are overrepresented in
human metastatic melanoma lymph nodes and inhibit the function of
infiltrating T cells. J. Immunol. 173:1444–1453.
35. Shimizu, J., S. Yamazaki, and S. Sakaguchi. 1999. Induction of tumor
immunity by removing CD25 CD4  T cells: a common basis be-
tween tumor immunity and autoimmunity. J. Immunol. 163:5211–5218.
36. Wolf, A.M., D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B.
Grubeck-Loebenstein. 2003. Increase of regulatory T cells in the pe-
ripheral blood of cancer patients. Clin. Cancer Res. 9:606–612.
37. Trzonkowski, P., E. Szmit, J. Mysliwska, A. Dobyszuk, and A. Mysliw-
ski. 2004. CD4 CD25  T regulatory cells inhibit cytotoxic activity
of T CD8  and NK lymphocytes in the direct cell-to-cell interaction.
Clin. Immunol. 112:258–267.
38. Ostroukhova, M., C. Seguin-Devaux, T.B. Oriss, B. Dixon-McCar-
thy, L. Yang, B.T. Ameredes, T.E. Corcoran, and A. Ray. 2004. Tol-
erance induced by inhaled antigen involves CD4  T cells expressing
membrane-bound TGF-  and FOXP3. J. Clin. Invest. 114:28–38.
39. Doubrovina, E.S., M.M. Doubrovin, E. Vider, R.B. Sisson, R.J.
O’Reilly, B. Dupont, and Y.M. Vyas. 2003. Evasion from NK cell im-
munity by MHC class I chain-related molecules expressing colon ade-
nocarcinoma. J. Immunol. 171:6891–6899.
40. Thornton, A.M., and E.M. Shevach. 1998. CD4 CD25  immunoreg-
ulatory T cells suppress polyclonal T cell activation by inhibiting inter-
leukin 2 production. J. Exp. Med. 188:287–296.
41. Thornton, A.M., and E.M. Shevach. 2000. Suppressor effector func-
tion of CD4  CD25  immunoregulatory T cells is antigen non-spe-
cific. J. Immunol. 164:183–190.
42. Piccirillo, C.A., and E.M. Shevach. 2001. Cutting edge: control of
CD8  T cell activation by CD4  CD25  immunoregulatory T cells.
J. Immunol. 167:1137–1142.
43. Brunkow, M.E., E.W. Jeffery, K.A. Hjerrild, B. Paeper, L.B. Clark,
S.A. Yasayko, J.E. Wilkinson, D. Galas, S.F. Ziegler, and F. Ramsdell.
2001. Disruption of a new forkhead/winged-helix protein, scurfin, re-
sults in the fatal lymphoproliferative disorder of the scurfy mouse. Nat.
Genet. 27:68–73.
44. Smyth, M.J., J. Swann, J.M. Kelly, E. Cretney, W.M. Yokoyama, A.
Diefenbach, T.J. Sayers, and Y. Hayakawa. 2004. NKG2D recognition
and perforin effector function mediate effective cytokine immunother-
apy of cancer. J. Exp. Med. 200:1325–1335.
45. Diefenbach, A., A.M. Jamieson, S.D. Liu, N. Shastri, and D.H. Raulet.
2000. Ligands for the murine NKG2D receptor: expression by tumor
cells and activation of NK cells and macrophages. Nat. Immunol.
1:119–126.
46. Hue, S., J.J. Mention, R.C. Monteiro, S. Zhang, C. Cellier, J.
Schmitz, V. Verkarre, N. Fodil, S. Bahram, N. Cerf-Bensussan, and S.
Caillat-Zucman. 2004. A direct role for NKG2D/MICA interaction in
villous atrophy during celiac disease. Immunity. 21:367–377.
47. Terme, M., E. Tomasello, K. Maruyama, F. Crepineau, N. Chaput, C.
Flament, J.P. Marolleau, E. Angevin, E.F. Wagner, B. Salomon, et al.
2004. IL-4 confers NK stimulatory capacity to murine dendritic cells: a
signaling pathway involving KARAP/DAP12-triggering receptor ex-
pressed on myeloid cell 2 molecules. J. Immunol. 172:5957–5966.